atrasentan has been researched along with endothelin-1 in 150 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (endothelin-1) | Trials (endothelin-1) | Recent Studies (post-2010) (endothelin-1) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 12,740 | 632 | 3,394 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (10.00) | 18.2507 |
| 2000's | 104 (69.33) | 29.6817 |
| 2010's | 28 (18.67) | 24.3611 |
| 2020's | 3 (2.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiou, WJ; Dixon, DB; Opgenorth, TJ; Wu-Wong, JR | 1 |
| Polakowski, JS; Pollock, DM | 1 |
| Chen, SJ; Chen, YF; DiCarlo, VS; Durand, J; Meng, QC; Oparil, S; Opgenorth, TJ; Wessale, JL | 1 |
| Burke, SE; Dayton, BD; Gagne, GD; Lubbers, NL; Opgenorth, TJ; Wegner, CD; Wessale, JL | 1 |
| Chiou, WJ; Dickinson, R; Opgenorth, TJ; Wu-Wong, JR | 1 |
| Borgeson, DD; Burnett, JC; Grantham, JA; Luchner, A; Opgenorth, TJ; Redfield, MM; Williamson, EE | 1 |
| Alexiou, K; Baumann, G; Dschietzig, T; Laule, M; Schrör, K; Stangl, K | 1 |
| He, G; Schiffrin, EL; Sharifi, AM; Touyz, RM | 1 |
| Clarke, N; Fuchs, LC; Giulumian, AD; Pollock, DM | 1 |
| Allcock, GH; Pollock, DM; Venema, RC | 1 |
| Bal, RB; Borre, AJ; Chiou, WJ; Dixon, DB; Hoffman, DJ; Marsh, KC; Nguyen, BN; Opgenorth, TJ; Szczepankiewicz, BG; von Geldern, TW; Wu-Wong, JR | 1 |
| Intengan, HD; Schiffrin, EL | 1 |
| Hashimoto, N; Kitano, R; Kuro, T; Matsumura, Y; Ohkita, M; Opgenorth, TJ; Taira, S; Takaoka, M | 1 |
| Adler, A; Chiou, WJ; Dixon, DB; Marsh, KC; Nguyen, B; Opgenorth, TJ; Sorensen, BK; Szczepankiewicz, BG; Tasker, AS; von Geldern, TW; Wang, L; Wessale, JL; Winn, M | 1 |
| Larouche, I; Schiffrin, EL | 1 |
| D'Orléans-Juste, P; Piovezan, AP; Rae, GA; Souza, GE | 1 |
| Chiou, WJ; Dayton, BD; Opgenorth, TJ; Wu-Wong, JR | 1 |
| Burke, SE; Cox, BF; Ford, TT; Fu, KI; Lubbers, NL; Nelson, RA; Padley, RJ; Wegner, CD | 1 |
| Kobayashi, Y; Kohnou, K; Kuro, T; Matsumura, Y; Opgenorth, TJ; Takaoka, M; Wessale, JL | 1 |
| Ballard, DE; Hijmering, ML; Honing, MLH; Morrison, PJ; Padley, RJ; Rabelink, TJ; Yang, YP | 1 |
| Boujedaini, H; Derumeaux, G; Henry, JP; Mulder, P; Opgenorth, T; Renet, S; Richard, V; Thuillez, C; Wessale, J | 1 |
| Cox, BF; Opgenorth, TJ; Preusser, LC; Reinhart, GA; Wegner, CD | 1 |
| Chen, YF; Oparil, S | 1 |
| Chiou, WJ; Opgenorth, TJ; von Geldern, T; Wessale, JL; Wu-Wong, JR | 1 |
| Adler, AL; Calzadilla, SV; Dixon, DB; Opgenorth, TJ; Padley, RJ; Wessale, JL; Wu-Wong, JR | 1 |
| De Gottardi, A; Reichen, J; Sägesser, H; Shaw, S | 1 |
| Alexander, BT; Bennett, WA; Cockrell, KL; Granger, JP; Massey, MB; Rinewalt, AN | 1 |
| Bianciotti, LG; de Bold, AJ | 1 |
| Alexander, BT; Cockrell, KL; Granger, JP; Herrington, JN; Rinewalt, AN | 1 |
| Derebail, VK; Pollock, DM; Pollock, JS; Yamamoto, T | 1 |
| Curtis, TM; Scholfield, CN | 1 |
| Bryan, PD; El-Shourbagy, TA; Padley, RJ; Sapochak, LB; Tames, MM | 1 |
| van der Boon, J | 1 |
| Chiou, WJ; Dixon, DB; Jae, HS; Liu, G; Opgenorth, TJ; Sorensen, BK; Tasker, A; von Geldern, TW; Winn, M; Wu-Wong, JR | 1 |
| Adler, AL; Calzadilla, SV; Dayton, BD; Jae, HS; Marsh, KC; Novosad, EI; Opgenorth, TJ; von Geldern, TW; Wessale, JL; Winn, M; Wu-Wong, JR | 1 |
| Abassi, Z; Francis, B; Hoffman, A; Ovcharenko, E; Wessale, J; Winaver, J | 1 |
| Bagnato, A; Cirilli, A; Flamini, S; Muller, A; Padley, R; Salani, D; Simeone, P; Venuti, A | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Padley, RJ; Rosanò, L; Salani, D; Spinella, F; Venuti, A | 1 |
| Boemke, W; Francis, RC; Höhne, C; Kaczmarczyk, G | 2 |
| Ayach, B; Battistini, B; Blouin, A; Gosselin, M; Jeng, AY; Opgenorth, TJ; Tsang, J; Wang, FH; Wessale, J; Wu-Wong, JR | 1 |
| Burke, SE; Cox, BF; Opgenorth, TJ; Preusser, LC; Reinhart, GA; Wegner, CD; Wessale, JL | 1 |
| Horio, T; Johnson, RJ; Kangawa, K; Kawano, Y; Suga, S; Yasui, N; Yoshihara, F | 1 |
| Breul, J; Carducci, MA; Daliani, DD; Nabulsi, AA; Nelson, JB; Schulman, CC; Vogelzang, NJ; Zonnenberg, BA | 1 |
| Gariepy, CE; Pollock, DM; Pollock, JS; Taylor, TA | 1 |
| Berthelot, A; Berthon, N; Fellmann, D; Laurant, P | 1 |
| Nisen, P | 1 |
| Ergul, A; Fuchs, LC; Giulumian, AD; Molero, MM; Portik-Dobos, V | 1 |
| Banes, AK; Chen, AF; Fink, GD; Galligan, JJ; Li, L; Watts, SW | 1 |
| Chen, AF; Fink, GD; Hesslinger, C; Kapatos, G; Kovesdi, I; Lookingland, KJ; Yang, XQ; Zheng, JS | 1 |
| Nelson, JB | 2 |
| Dewey, ER; Neerhof, MG; Thaete, LG | 1 |
| da Silva, AA; Hall, JE; Kuo, JJ; Tallam, LS | 1 |
| Lee, D | 1 |
| Fisher, M | 1 |
| Brink, AK; Nelson, JB; Pecher, S; Pflug, BR | 1 |
| Fujimori, A; Fujiyasu, N; Koakutsu, A; Miyata, K; Sasamata, M; Sato, S; Shibasaki, K; Sudoh, K; Tanahashi, M; Tanaka, S; Yuyama, H | 1 |
| Ghilardi, JR; Lindsay, TH; Luger, NM; Mantyh, PW; Peters, CM; Pomonis, JD; Sevcik, MA | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F | 1 |
| Chen, AF; Chen, MS; Lin, SB; Luo, JD; Wang, YZ; Xu, FP; Yi, Q | 1 |
| Cucchiarelli, VE; Fortepiani, LA; Gomez-Sanchez, CE; Reckelhoff, JF; Romero, DG; Santacruz, F; Yanes, LL | 1 |
| Fujimori, A; Fujiyasu, N; Miyata, K; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Sudoh, K; Ukai, M; Yuyama, H | 1 |
| Chancellor, MB; de Groat, WC; Igawa, Y; Kamo, I; Nelson, JB; Nishizawa, O; Ogawa, T; Pflug, BR; Seki, S; Yoshimura, N | 1 |
| Carducci, M; Jimeno, A | 2 |
| Carducci, M; Latini, A; Simeone, P; Teson, M; Venuti, A | 1 |
| Fujita, M; Gariepy, CE; Kanazawa, M; Matsumoto, N; Matsumura, Y; Takaoka, M; Yamamoto, S; Yanagisawa, M | 1 |
| Chang, M; El-Shourbagy, T; Wang, PG; Wei, J | 1 |
| Fujimori, A; Miyata, K; Noguchi, Y; Ohtake, A; Sasamata, M; Sato, S; Sudoh, K; Ukai, M; Yuyama, H | 1 |
| Abassi, Z; Francis, B; Hoffman, A; Karram, T; Winaver, J | 1 |
| D'Orléans-Juste, P; Fecteau, MH; Honoré, JC; Wessale, JL | 1 |
| Bagnato, A; Cirilli, A; Muller, A; Simeone, P; Venuti, A | 1 |
| Bkaily, G; Brochu, I; D'Orleans-Juste, P; Fecteau, MH; Honoré, JC; Labonté, J | 1 |
| Bennett, W; Cockrell, K; Granger, JP; LaMarca, BB; Sullivan, E | 1 |
| Berthiaume, N; Opgenorth, TJ; Wessale, JL; Zinker, BA | 1 |
| Dorrance, AM; Ergul, A; Fagan, SC; Harris, AK; Hutchinson, JR; Johnson, MH; Sachidanandam, K; Stepp, DW | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Opocensky, M; Vanêcková, I; Vernerová, Z | 1 |
| Clines, GA; Guise, TA | 1 |
| Cook, AK; Imig, JD; Inscho, EW; Pollock, DM | 1 |
| Berthiaume, N; Carlson, CJ; Rondinone, CM; Zinker, BA | 1 |
| Cella, D; Fishman, M; Mulani, P; Petrylak, DP; Teigland, C; Young, J | 1 |
| Ergul, A; Song, W | 1 |
| Choueiri, TK; Garcia, JA; Thakkar, SG | 1 |
| Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR | 1 |
| Chichorro, JG; Rae, GA; Zampronio, AR | 1 |
| Chang, SS; Rumohr, JA | 1 |
| Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
| Al-Khoury, J; Bkaily, G; Chahine, M; D'Orléans-Juste, P; Jacques, D | 1 |
| Feng, KT; Guo, X; Hong, MH; Liang, WJ; Mai, HQ; Mo, HY; Ye, YL; Zeng, ZY; Zhang, CQ | 1 |
| Hasegawa, Y; Kawanishi, H; Matsumura, Y; Nakano, D; Ohkita, M; Ohno, Y; Takaoka, M | 1 |
| Fischgräbe, J; Götte, M; Kersting, C; Kiesel, L; Smollich, M; Wülfing, P | 1 |
| Caron, A; Dupuis, J; Sauvageau, S; Thorin, E | 1 |
| Banes-Berceli, AK; Ketsawatsomkron, P; Marrero, MB; Ogbi, S; Patel, B; Pollock, DM | 1 |
| Belcher, E; Harding, SE; Mitchell, JA; Patel, TA; Warner, TD | 1 |
| Donckier, JE; Flamion, B; Mertens-Strijthagen, J | 1 |
| Fink, G; Lau, Y; Li, M; Osborn, J; Watts, S | 1 |
| Ergul, A; Harris, AK; Hutchinson, JR; Johnson, MH; Muller, E; Portik-Dobos, V; Sachidanandam, K | 1 |
| Demirakca, S; Dieckmann, R; Gebhard, MM; Gorenflo, M; Hagl, S; Herpel, E; Klimpel, H; Neumayer, S; Ullmann, MV | 1 |
| Lalich, M; Liu, G; McNeel, DG; Wilding, G | 1 |
| Chang, NC; Chen, CC; Lee, TM; Lin, MS | 1 |
| Elgebaly, MM; Ergul, A; Harris, AK; Li, W; Sachidanandam, K | 1 |
| Elgebaly, MM; Ergul, A; Harris, AK; Hutchinson, JR; Mezzetti, EM; Portik-Dobos, V; Sachidanandam, K | 1 |
| Carneiro, FS; Carneiro, ZN; Ergul, A; Giachini, FR; Leite, R; Lima, VV; Nunes, KP; Tostes, RC; Webb, RC | 1 |
| Boemke, W; Francis, RC; Höhne, C; Kaisers, U; Klein, A; Pickerodt, P | 1 |
| Bkaily, G; Carrier, E; D'Orleans-Juste, P; Fecteau, MH; Honoré, JC; Tirapelli, CR | 1 |
| Fukumoto, T; Matsumura, Y; Ohkita, M; Tawa, M | 1 |
| Holmes, DR; Kent, B; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E | 1 |
| Dawson, NA | 1 |
| Carducci, M; Chin, JL; Love, W; Nelson, JB; Qian, J; Saad, F; Schulman, CC; Sleep, DJ; Steinberg, J | 1 |
| Carneiro, FS; Carneiro, ZN; Clinton Webb, R; Ergul, A; Giachini, FR; Leite, R; Lima, VV; Nogueira, EF; Nunes, KP; Rainey, WE; Tostes, RC | 1 |
| Callera, GE; Carneiro, FS; Carneiro, ZN; Ergul, A; Giachini, FR; Lima, VV; Tostes, RC; Webb, RC; Zemse, SM | 1 |
| Nakano, D; Pollock, DM | 1 |
| Chung, SK; Chung, SS; Leung, JW | 1 |
| Gariepy, CE; Tykocki, NR; Watts, SW | 1 |
| Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F | 1 |
| Bolenz, C; Bremer, C; Eltze, E; Herrmann, E; Hertle, L; Persigehl, T; Tiemann, A; Wülfing, C | 1 |
| Cockrell, K; Dechend, R; Glover, P; LaMarca, B; Martin, JN; Murphy, SR; Parrish, M; Ray, LF; Roberts, L; Ryan, MJ; Wallukat, G; Wenzel, K | 1 |
| Carneiro, FS; Carneiro, ZN; Carvalho, MH; Ergul, A; Fortes, ZB; Giachini, FR; Lima, VV; Pollock, DM; Saleh, MA; Tostes, RC; Webb, RC | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Michels, K; Wülfing, P | 1 |
| Cockrell, K; Granger, JP; LaMarca, BB; Murphy, SR | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Kujal, P; Vaneckova, I; Vernerová, Z | 1 |
| Boemke, W; Francis, RC; Höhne, C; Kaisers, UX; Klein, A; Pickerodt, PA | 1 |
| Ariaans, MP; Brookes, ZL; Brown, NJ; Kaufman, S; Mansart, A; Reilly, CS; Ross, JJ; Ruff, LJ | 1 |
| Hamel, E; Ongali, B; Papadopoulos, P | 1 |
| Avedanian, L; Bkaily, G; D'Orleans-Juste, P; Jacques, D; Nader, M; Riopel, J | 1 |
| Harris, NR; Leskova, W; Wang, Z; Yadav, AS | 1 |
| Lennon, R; Lerman, A; Lerman, LO; Mathew, V; Nelson, RE; Prasad, A; Pumper, GM; Raichlin, E; Reriani, M; Rihal, C | 1 |
| Boesen, EI; Pollock, DM; Pollock, JS; Saleh, MA; Savin, VJ | 1 |
| Ayajiki, K; Fukumoto, T; Geddawy, A; Imamura, T; Matsumura, Y; Ohkita, M; Okamura, T; Tawa, M; Yamashita, N | 1 |
| Buchanan, C; Lago Huvelle, MA; Peters, MG | 1 |
| Chen, CC; Hsu, YJ; Lee, TM | 1 |
| Corn, PG; Dayyani, F; Gallick, GE; Logothetis, CJ | 1 |
| Coucha, M; Ergul, A; Li, W | 1 |
| Kimura, K; Koyama, M; Matsumura, Y; Ohkita, M | 1 |
| Heath, J; LaMarca, B; Martin, JN; Moseley, J; Novotny, S; Owens, MY; Wallace, K | 1 |
| Andress, D; Becker, K; Johnson, AC; Zager, RA | 1 |
| Bkaily, G; Brochu, I; D'Orléans-Juste, P; Desbiens, L; Gobeil, F; Houde, M; Semaan, W; Simard, E | 1 |
| Chang, NC; Chung, TH; Lee, TM; Lin, SZ | 1 |
| Batlle, D; Chou, JC; Fawzi, AA; Rollins, SD; Ye, M | 1 |
| Andress, D; Brennan, JJ; Coll, B; Correa-Rotter, R; de Zeeuw, D; Houser, M; Kohan, D; Lambers Heerspink, HJ; Makino, H; Parving, HH; Perkovic, V; Pritchett, Y; Remuzzi, G; Tang, H; Tobe, SW; Toto, R; Viberti, G | 1 |
| Coelho, SC; Fraulob-Aquino, JC; Huo, KG; Offermanns, S; Paradis, P; Rautureau, Y; Rehman, A; Schiffrin, EL | 1 |
| Harris, A; Kyle, PB; Morris, R; Owens, MY; Spencer, SK; Wallace, K; Williams, JM | 1 |
| Alexander, BT; Intapad, S; Ojeda, NB; Royals, TP; Varney, E | 1 |
| Jin, C; Johnston, JG; Pollock, DM; Speed, JS | 1 |
| Agharazii, M; Gauthier-Bastien, A; Larivière, R; Mac-Way, F; Richard, DE; St-Hilaire, J; Ung, RV | 1 |
| Egido, J; Gomez-Guerrero, C; Gonzalez Parra, E; Mas, S; Rojas-Rivera, J; Ruiz-Ortega, M; Sanz, AB | 1 |
| Bądzyńska, B; Hojná, S; Kompanowska-Jezierska, E; Sadowski, J; Vaneckova, I | 1 |
| Fernandez-Fernandez, B; Ortiz, A | 1 |
| Červenka, L; Gawrys, O; Jíchová, Š; Kala, P; Kompanowska-Jezierska, E; Maxová, H; Miklovič, M; Sadowski, J; Škaroupková, P; Táborský, M; Vaněčková, I; Vaňourková, Z; Veselka, J; Walkowska, A | 1 |
13 review(s) available for atrasentan and endothelin-1
| Article | Year |
|---|---|
Endothelial dysfunction in the pulmonary vascular bed.
Topics: Animals; Antihypertensive Agents; Atrasentan; Bosentan; Controlled Clinical Trials as Topic; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Hypoxia; Lung Diseases, Obstructive; Nitric Oxide; Oligopeptides; Peptides, Cyclic; Piperidines; Pulmonary Circulation; Pyrrolidines; Receptors, Endothelin; RNA, Messenger; Sulfonamides; Time Factors; Vasoconstriction; Vasodilation | 2000 |
Endothelin inhibition: novel therapy for prostate cancer.
Topics: Antineoplastic Agents; Atrasentan; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2003 |
Atrasentan: targeting the endothelin axis in prostate cancer.
Topics: Atrasentan; Carcinoma; Clinical Trials, Phase III as Topic; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A | 2004 |
Endothelin receptor antagonists.
Topics: Apoptosis; Atrasentan; Biomarkers, Tumor; Clinical Trials as Topic; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Receptors, Endothelin; Treatment Outcome | 2005 |
Mechanisms and treatment for bone metastases.
Topics: Animals; Atrasentan; Bone Neoplasms; Cell Adhesion Molecules; Cytokines; Diphosphonates; Endothelin-1; Female; Gene Expression Regulation, Neoplastic; Humans; Hypercalcemia; Immunotherapy; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Nude; Neoplasm Proteins; Osteoblasts; Osteolysis; Pain; Pain Management; Pyrrolidines; Xenograft Model Antitumor Assays | 2004 |
Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Topics: Atrasentan; Drug Resistance, Neoplasm; Endothelin-1; Gonadal Steroid Hormones; Humans; Male; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Pyrrolidines; Quality of Life | 2006 |
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2006 |
Atrasentan: a rationally designed targeted therapy for cancer.
Topics: Animals; Antineoplastic Agents; Atrasentan; Drug Delivery Systems; Drug Design; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic | 2006 |
Endothelin receptor antagonists in cancer therapy.
Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides | 2007 |
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Bosentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Homozygote; Hypertension; Male; Podocytes; Pyrrolidines; Rats; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2009 |
Metastasis suppressors: basic and translational advances.
Topics: Animals; Atrasentan; Endothelin-1; Genes, Tumor Suppressor; Humans; Neoplasm Metastasis; Pyrrolidines; Tumor Suppressor Proteins | 2011 |
Novel therapies for metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Anilides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Atrasentan; Benzamides; Bevacizumab; Biomarkers, Tumor; Bone Remodeling; Cancer Vaccines; Clinical Trials as Topic; Clusterin; Dasatinib; Denosumab; Endothelin-1; Humans; Immunotherapy; Indoles; Ipilimumab; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrroles; Pyrrolidines; RANK Ligand; Receptor Cross-Talk; Receptors, Androgen; Signal Transduction; Sunitinib; Taxoids; Thiazoles; Tissue Extracts; Treatment Failure; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Atrasentan for the treatment of diabetic nephropathy.
Topics: Animals; Atrasentan; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelin-1; Humans; Proteinuria; Pyrrolidines; Renal Insufficiency, Chronic | 2017 |
8 trial(s) available for atrasentan and endothelin-1
| Article | Year |
|---|---|
Selective ET(A) receptor antagonism with ABT-627 attenuates all renal effects of endothelin in humans.
Topics: Adult; Atrasentan; Calcium Channel Blockers; Cross-Over Studies; Diuresis; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Female; Hemodynamics; Humans; Kidney; Male; Nifedipine; Pyrrolidines; Receptor, Endothelin A; Renal Circulation; Vasoconstrictor Agents | 2000 |
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Bone Remodeling; Bone Resorption; Collagen; Collagen Type I; Double-Blind Method; Endothelin-1; Humans; Male; Peptides; Prostatic Neoplasms; Pyrrolidines | 2003 |
Clinical trials of atrasentan in hormone-refractory prostate cancer.
Topics: Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Neoplasm Metastasis; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Survival Analysis; Treatment Outcome | 2003 |
The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Atrasentan; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endothelin-1; Follow-Up Studies; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Risk Assessment; Treatment Outcome | 2002 |
Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis.
Topics: Adult; Antihypertensive Agents; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Edema; Endothelin A Receptor Antagonists; Endothelin-1; Female; Follow-Up Studies; Humans; Hypertension; Kidney; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Pyrrolidines; Receptor, Endothelin A; Risk Factors; Treatment Outcome | 2008 |
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Atrasentan; Disease Progression; Double-Blind Method; Endothelin-1; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prognosis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome | 2008 |
Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis.
Topics: Adult; Atrasentan; Blood Glucose; Blood Pressure; Coronary Artery Disease; Coronary Circulation; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Rate; Humans; Kidney; Lipoprotein(a); Male; Microcirculation; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrrolidines; Receptor, Endothelin A; Triglycerides; Uric Acid | 2010 |
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrasentan; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Endothelin-1; Female; Humans; Kidney Function Tests; Lipids; Male; Middle Aged; Pyrrolidines | 2014 |
129 other study(ies) available for atrasentan and endothelin-1
| Article | Year |
|---|---|
Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics.
Topics: Acetamides; Animals; Atrasentan; Azepines; Binding, Competitive; Bosentan; Cells, Cultured; CHO Cells; Cricetinae; Dioxoles; Endothelin Receptor Antagonists; Endothelin-1; Hydrolysis; Indoles; Phosphatidylinositols; Pyrrolidines; Rats; Serum Albumin, Bovine; Sulfonamides; Swine | 1997 |
ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Protein Precursors; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 1997 |
The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomegaly; Endothelin Receptor Antagonists; Endothelin-1; Heart Rate; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Artery; Pyrrolidines; Rats; Receptor, Endothelin A | 1997 |
Selective antagonism of the ET(A) receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs.
Topics: Angioplasty, Balloon; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Blood Pressure; Captopril; Carotid Artery Injuries; Carotid Artery, Common; Collagen; Endothelin Receptor Antagonists; Endothelin-1; Hyperplasia; Iliac Artery; Male; Muscle, Smooth, Vascular; Pyrrolidines; Receptor, Endothelin A; Swine; Swine, Miniature; Tunica Intima | 1997 |
Endothelin attenuates apoptosis in human smooth muscle cells.
Topics: Angiotensin II; Annexin A5; Apoptosis; Atrasentan; Cell Survival; DNA Fragmentation; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Male; Muscle, Smooth; Paclitaxel; Pericardium; Phosphatidylserines; Propidium; Prostate; Pyrrolidines | 1997 |
Chronic oral endothelin type A receptor antagonism in experimental heart failure.
Topics: Administration, Oral; Animals; Atrasentan; Atrial Natriuretic Factor; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Heart; Heart Failure; Hemodynamics; Kidney; Male; Pyrrolidines; Receptor, Endothelin A; Sodium; Vasoconstriction | 1998 |
Coronary constriction and consequent cardiodepression in pulmonary embolism are mediated by pulmonary big endothelin and enhanced in early endothelial dysfunction.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Arteriosclerosis; Aspartic Acid Endopeptidases; Atrasentan; Coronary Circulation; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Endothelins; Endothelium, Vascular; Glycopeptides; In Vitro Techniques; Male; Metalloendopeptidases; Myocardial Contraction; Oligopeptides; Peptides, Cyclic; Protein Precursors; Pulmonary Embolism; Pyrrolidines; Rabbits; Thromboxane B2; Vasoconstriction | 1998 |
Vascular endothelin-1 expression and effect of an endothelin ETA antagonist on structure and function of small arteries from stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Blood Vessels; Blotting, Northern; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Mesenteric Arteries; Muscle Contraction; Organ Size; Pyrrolidines; Rats; Rats, Inbred SHR; Receptor, Endothelin A; RNA, Messenger | 1998 |
Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Coronary Vessels; Desoxycorticosterone; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Male; Mesenteric Arteries; Potassium Chloride; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium Chloride; Vasoconstriction | 1998 |
ETA receptor blockade attenuates the hypertension but not renal dysfunction in DOCA-salt rats.
Topics: Animals; Atrasentan; Blood Pressure; Creatinine; Desoxycorticosterone; Endothelin Receptor Antagonists; Endothelin-1; Glomerular Filtration Rate; Hypertension; Kidney; Kidney Cortex; Kidney Medulla; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Messenger; Sodium, Dietary; Stereoisomerism; Time Factors; Transcription, Genetic; Water-Electrolyte Balance | 1998 |
The effects of diminishing albumin binding to some Endothelin receptor antagonists.
Topics: Animals; Atrasentan; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-3; Humans; Male; Protein Binding; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Serum Albumin; Stereoisomerism | 1998 |
Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1.
Topics: Animals; Atrasentan; Biomechanical Phenomena; Blood Pressure; Disease Models, Animal; Elasticity; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Pyrrolidines; Rats; Receptor, Endothelin A; Sodium Chloride; Vascular Resistance | 1998 |
Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats.
Topics: Animals; Aorta; Atrasentan; Desoxycorticosterone; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-2; Hypertension; Male; Nephrectomy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin | 1999 |
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity.
Topics: Acetanilides; Animals; Atrasentan; Blood Pressure; Cell Line; Endothelin Receptor Antagonists; Endothelin-1; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B | 1999 |
Cardiac microvasculature in DOCA-salt hypertensive rats : effect of endothelin ET(A) receptor antagonism.
Topics: Animals; Atrasentan; Coronary Circulation; Coronary Vessels; Desoxycorticosterone; Endothelin Receptor Antagonists; Endothelin-1; Heart; Hypertension, Renovascular; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptors, Endothelin; Sodium Chloride, Dietary | 1999 |
Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation.
Topics: Animals; Atrasentan; Capsaicin; Edema; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hyperalgesia; Male; Mice; Nociceptors; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Viper Venoms | 2000 |
Direct determination of endothelin receptor antagonist levels in plasma using a scintillation proximity assay.
Topics: Animals; Atrasentan; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Endothelin Receptor Antagonists; Endothelin-1; Humans; Pyrrolidines; Radioligand Assay; Rats; Receptors, Endothelin; Recombinant Proteins; Scintillation Counting; Spectrometry, Fluorescence | 2000 |
Evidence for vasoconstriction mediated by the endothelin-B receptor in domestic swine.
Topics: Angiotensin II; Animals; Animals, Domestic; Atrasentan; Blood Pressure; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Femoral Artery; Protein Precursors; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Swine; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Viper Venoms | 2000 |
Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Ischemia; Kidney; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Reperfusion Injury | 2000 |
Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.
Topics: Animals; Atrasentan; Blood Pressure; Collagen; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Myocardial Infarction; Myocardium; Pyrrolidines; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Ventricular Function, Left | 2000 |
Endothelin and ET(A) receptors in long-term arterial pressure homeostasis in conscious nonhuman primates.
Topics: Animals; Atrasentan; Blood Pressure; Endothelin Receptor Antagonists; Endothelin-1; Heart Rate; Hematocrit; Homeostasis; Kinetics; Macaca fascicularis; Male; Potassium; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin; Sodium | 2000 |
'Irreversible' endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects.
Topics: Animals; Atrasentan; Blood Pressure; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Humans; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 2000 |
Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level.
Topics: Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Male; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B | 2000 |
Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats.
Topics: Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Portal; Male; Portal Pressure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B | 2000 |
Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure.
Topics: Animals; Atrasentan; Blood Pressure; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Hypertension; Kidney Cortex; Kidney Medulla; Perfusion; Pregnancy; Pregnancy Complications, Cardiovascular; Protein Precursors; Pyrrolidines; Rats; Receptor, Endothelin A; RNA, Messenger; Uterus | 2001 |
Modulation of cardiac natriuretic peptide gene expression following endothelin type A receptor blockade in renovascular hypertension.
Topics: Analysis of Variance; Animals; Atrasentan; Atrial Natriuretic Factor; Blotting, Northern; Collagen; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Heart Atria; Heart Ventricles; Hypertension, Renovascular; Male; Natriuretic Peptide, Brain; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Messenger | 2001 |
Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension.
Topics: Angiotensin II; Animals; Atrasentan; Blood Pressure; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Gene Expression Regulation; Glomerular Filtration Rate; Hemodynamics; Hypertension; Infusions, Intravenous; Kidney; Kidney Cortex; Kidney Medulla; Male; Protein Precursors; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Renal Circulation; RNA, Messenger; Transcription, Genetic; Urodynamics | 2001 |
Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; Desoxycorticosterone; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Kidney; Male; Natriuresis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 2000 |
Evidence for two endothelin Et(A) receptor subtypes in rabbit arteriolar smooth muscle.
Topics: Animals; Arterioles; Atrasentan; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Choroid; Culture Techniques; Endothelin Receptor Antagonists; Endothelin-1; Female; Ion Transport; Male; Membrane Potentials; Muscle, Smooth, Vascular; Oligopeptides; Patch-Clamp Techniques; Peptides, Cyclic; Piperidines; Pyrrolidines; Rabbits; Receptor, Endothelin A; Receptors, Endothelin | 2001 |
Determination of atrasentan by high performance liquid chromatography with fluorescence detection in human plasma.
Topics: Antineoplastic Agents; Atrasentan; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Endothelin-1; Fluorescence; Humans; Molecular Structure; Pyrrolidines; Quality Control; Reference Standards; Sensitivity and Specificity; Temperature | 2001 |
New drug slows prostate-cancer progression.
Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2002 |
Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
Topics: Animals; Arachidonic Acid; Atrasentan; Binding, Competitive; Cell Line; CHO Cells; Cricetinae; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hydrolysis; Iodine Radioisotopes; Phosphatidylinositols; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Sulfonamides; Transfection; Vasodilator Agents | 2002 |
Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
Topics: Analysis of Variance; Animals; Aorta; Atrasentan; Dogs; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Female; Humans; In Vitro Techniques; Macaca fascicularis; Male; Muscle, Smooth, Vascular; Pyrrolidines; Rabbits; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasoconstrictor Agents; Vasodilator Agents; Viper Venoms | 2002 |
Effects of endothelin receptors ET(A) and ET(B) blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure.
Topics: Animals; Atrasentan; Blood Pressure; Endothelin Receptor Antagonists; Endothelin-1; Glomerular Filtration Rate; Heart Failure; Kidney; Male; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Renal Circulation; Vascular Resistance | 2002 |
Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma.
Topics: Atrasentan; Cell Division; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Papillomaviridae; Peptides, Cyclic; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.
Topics: Atrasentan; Binding, Competitive; Cell Division; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ovarian Neoplasms; Pyrrolidines; Receptor, Endothelin A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2002 |
Haemodynamic and hormonal changes during haemorrhage in conscious dogs treated with an endothelin-A receptor antagonist.
Topics: Action Potentials; Acute Disease; Angiotensin II; Animals; Atrasentan; Blood Pressure; Cardiac Output; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Hemorrhage; Norepinephrine; Pyrrolidines; Random Allocation; Receptor, Endothelin A; Vascular Resistance; Vasodilator Agents; Vasopressins | 2002 |
Effects of a selective endothelin A receptor antagonist, ABT-627, in healthy normotensive anaesthetized rats developing acute pulmonary air embolism.
Topics: Acute Disease; Animals; Atrasentan; Embolism, Air; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-3; Gene Expression; Lung; Male; Models, Animal; Oxygen; Pulmonary Embolism; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin | 2002 |
Hypertension induced by blockade of ET(B) receptors in conscious nonhuman primates: role of ET(A) receptors.
Topics: Animals; Antineoplastic Agents; Atrasentan; Blood Pressure; Consciousness; Endothelin Receptor Antagonists; Endothelin-1; Heart Rate; Homeostasis; Hypertension; Macaca fascicularis; Male; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Telemetry | 2002 |
Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms.
Topics: Albuminuria; Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Hypertrophy; Hypokalemia; Kidney; Kidney Diseases; Kidney Tubules; Male; Potassium; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B | 2003 |
Unique endothelin receptor binding in kidneys of ETB receptor deficient rats.
Topics: Animals; Atrasentan; Binding, Competitive; Down-Regulation; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-3; Gene Deletion; Kidney; Kidney Cortex; Kidney Medulla; Male; Pyrrolidines; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin | 2003 |
Effect of magnesium on mRNA expression and production of endothelin-1 in DOCA-salt hypertensive rats.
Topics: Animals; Aorta; Atrasentan; Blood Pressure; Desoxycorticosterone; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Heart Rate; Heart Ventricles; Hypertension; Kidney; Magnesium Oxide; Male; Organ Size; Pyrrolidines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2003 |
New principles in the treatment of hormonal refractory prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Humans; Male; Prostatic Neoplasms; Pyrrolidines | 2003 |
Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation.
Topics: Animals; Aorta, Thoracic; Atrasentan; Blood Pressure; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Male; Matrix Metalloproteinases; Pyrrolidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Endothelin A; Stress, Physiological; Up-Regulation | 2003 |
NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension.
Topics: Acetophenones; Allopurinol; Animals; Atrasentan; Desoxycorticosterone; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Male; NADPH Oxidases; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Superoxides; Vasoconstriction; Vasoconstrictor Agents; Venae Cavae; Viper Venoms; Xanthine Oxidase | 2003 |
Gene transfer of human guanosine 5'-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension.
Topics: Acetophenones; Animals; Antioxidants; Atrasentan; Biopterins; Carotid Arteries; Cyclic N-Oxides; Desoxycorticosterone; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Gene Transfer Techniques; Genetic Therapy; GTP Cyclohydrolase; Humans; Hypertension; In Vitro Techniques; Male; Nitric Oxide; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium Chloride; Spin Labels; Superoxides; Vasodilation | 2003 |
Endothelin and the regulation of uterine and placental perfusion in hypoxia-induced fetal growth restriction.
Topics: Animals; Atrasentan; Blood Flow Velocity; Blood Pressure; Cobalt Radioisotopes; Endothelin A Receptor Antagonists; Endothelin-1; Female; Fetal Growth Retardation; Fetal Hypoxia; Fetus; Gestational Age; Kidney; Microspheres; Oxygen; Placenta; Pregnancy; Pyrrolidines; Rats; Rats, Sprague-Dawley; Uterus | 2004 |
Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension.
Topics: Adipose Tissue; Animals; Atrasentan; Blood Pressure; Body Weight; Eating; Endothelin A Receptor Antagonists; Endothelin-1; Fats; Heart Rate; Hormones; Hypertension; Kidney; Male; Obesity; Pyrrolidines; Rats; Rats, Sprague-Dawley; Viscera | 2004 |
Effect of angiotensin II and endothelin-1 receptor blockade on the haemodynamic and hormonal changes after acute blood loss and after retransfusion in conscious dogs.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Blood Transfusion; Cardiac Output; Dogs; Endothelin-1; Epinephrine; Female; Glomerular Filtration Rate; Hemodynamics; Hemorrhage; Losartan; Norepinephrine; Pyrrolidines; Receptor, Endothelin A; Stroke Volume; Urine; Vascular Resistance; Vasopressins | 2004 |
Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines.
Topics: Atrasentan; Endothelin A Receptor Antagonists; Endothelin-1; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured | 2004 |
Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain.
Topics: Analgesics, Non-Narcotic; Animals; Atrasentan; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Hindlimb; Male; Mice; Mice, SCID; Pain; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Sulfonamides; Time Factors; Viper Venoms | 2004 |
Endothelin and the tumorigenic component of bone cancer pain.
Topics: Analysis of Variance; Animals; Atrasentan; Behavior, Animal; Bone Neoplasms; Calcitonin Gene-Related Peptide; Disease Models, Animal; Dynorphins; Endothelin Receptor Antagonists; Endothelin-1; Ganglia, Spinal; Gene Expression Regulation, Neoplastic; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Mice; Mice, Inbred Strains; Pain; Pain Measurement; Pyrrolidines; Receptors, Endothelin; Sarcoma; Sciatic Nerve; Time Factors | 2004 |
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Topics: Animals; Atrasentan; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Isoenzymes; Luciferases; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Nitrobenzenes; Ovarian Neoplasms; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Receptor, Endothelin A; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes.
Topics: Animals; Animals, Newborn; Antioxidants; Atrasentan; Atrial Natriuretic Factor; Cardiomegaly; Catalase; Cell Size; Cells, Cultured; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Leptin; Myocytes, Cardiac; Obesity; Oxidative Stress; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2004 |
Role of endothelin in mediating postmenopausal hypertension in a rat model.
Topics: Animals; Atrasentan; Endothelin A Receptor Antagonists; Endothelin-1; Endothelins; Female; Gene Expression; Hypertension; Kidney Cortex; Postmenopause; Pyrrolidines; Rats; Rats, Inbred SHR; Receptor, Endothelin A; RNA, Messenger | 2005 |
Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
Topics: Atrasentan; Binding, Competitive; Blood Pressure; Cell Line; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Iodine Radioisotopes; Oligopeptides; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrrolidines; Radioligand Assay; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Time Factors; Viper Venoms | 2004 |
Differential roles of peripheral and spinal endothelin receptors in the micturition reflex in rats.
Topics: Afferent Pathways; Animals; Atrasentan; Capsaicin; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Injections, Spinal; Muscle Hypertonia; Naloxone; Nerve Fibers, Unmyelinated; Peripheral Nerves; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Receptors, Opioid; Reflex; Spinal Cord; Urinary Bladder; Urination; Urodynamics | 2004 |
Endothelin-1 could be one of the targets of psoriasis therapy.
Topics: Atrasentan; Cells, Cultured; Dermatologic Agents; Endothelin-1; Humans; Keratinocytes; Psoriasis; Pyrrolidines | 2004 |
Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts.
Topics: Amiloride; Animals; Animals, Genetically Modified; Atrasentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Gene Deletion; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Norepinephrine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Regional Blood Flow; Ventricular Pressure | 2005 |
High-throughput determination of atrasentan in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Topics: Antineoplastic Agents; Atrasentan; Chromatography, High Pressure Liquid; Endothelin-1; Humans; Pyrrolidines; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2005 |
Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Topics: Administration, Oral; Animals; Atrasentan; Binding, Competitive; Biological Availability; Blood Pressure; Bosentan; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Injections, Intravenous; Muscle, Smooth, Vascular; Oligopeptides; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Viper Venoms | 2004 |
Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Infusion Pumps, Implantable; Kidney; Male; Natriuresis; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Time Factors; Vasoconstriction; Vasodilation | 2004 |
Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster.
Topics: Animals; Atrasentan; Blood Pressure; Cricetinae; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelins; Injections, Intravenous; Male; Mesocricetus; Peptide Fragments; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B | 2004 |
Targeting endothelin receptor type A in human cervical carcinoma cells.
Topics: Antineoplastic Agents; Atrasentan; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Human papillomavirus 16; Humans; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Uterine Cervical Neoplasms | 2004 |
Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster.
Topics: Anesthesia; Animals; Atrasentan; Blood Pressure; Consciousness; Cricetinae; Dose-Response Relationship, Drug; Endothelin B Receptor Antagonists; Endothelin-1; Endothelins; Endothelium, Vascular; Hypertension; Male; Mesocricetus; Muscle, Smooth, Vascular; Peptide Fragments; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B | 2005 |
Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats.
Topics: Animals; Aorta; Atrasentan; Blood Pressure; Endothelin A Receptor Antagonists; Endothelin-1; Endothelins; Female; Hypertension; Kidney; Placenta; Pregnancy; Pregnancy Complications, Cardiovascular; Pyrrolidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tumor Necrosis Factor-alpha | 2005 |
Metabolic responses with endothelin antagonism in a model of insulin resistance.
Topics: Animals; Area Under Curve; Atrasentan; Blood Glucose; Endothelin A Receptor Antagonists; Endothelin-1; Fatty Acids, Nonesterified; Insulin; Insulin Resistance; Pyrrolidines; Rats; Rats, Zucker | 2005 |
Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1.
Topics: Animals; Atrasentan; Blood Glucose; Cerebral Arteries; Collagen; Diabetes Mellitus, Type 2; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Matrix Metalloproteinases; Neovascularization, Physiologic; Pyrrolidines; Rats; Telencephalon | 2005 |
Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Endothelin A Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heart Ventricles; Hypertension; Kidney; Male; Myocardium; Organ Size; Osmolar Concentration; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Renin; Sodium Chloride, Dietary; Sulfonamides; Survival Analysis | 2005 |
ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin.
Topics: Animals; Arterioles; Atrasentan; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelins; Male; Peptide Fragments; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Vasoconstriction; Viper Venoms | 2005 |
Endothelin antagonism improves hepatic insulin sensitivity associated with insulin signaling in Zucker fatty rats.
Topics: Animals; Atrasentan; Blood Pressure; Body Weight; Drinking; Endothelin-1; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Muscle, Skeletal; Obesity; Pyrrolidines; Rats; Rats, Zucker; Signal Transduction | 2005 |
Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size.
Topics: Animals; Aorta; Atrasentan; Blood Vessels; Diabetes Mellitus, Type 2; Endothelin Receptor Antagonists; Endothelin-1; Gene Expression Profiling; Gene Expression Regulation; Hyperglycemia; Male; Matrix Metalloproteinases; Mesenteric Arteries; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Reference Values | 2006 |
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Topics: Antineoplastic Agents; Atrasentan; Clinical Trials as Topic; Disease Progression; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Male; Neoplasms; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptors, Endothelin | 2006 |
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold Temperature; Dexamethasone; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelin-1; Endothelins; Grooming; Hyperalgesia; Indomethacin; Male; Maxillary Nerve; Nerve Compression Syndromes; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Trigeminal Neuralgia | 2006 |
Endothelin ET(B) receptor antagonist reduces mechanical allodynia in rats with trigeminal neuropathic pain.
Topics: Animals; Atrasentan; Bosentan; Drug Therapy, Combination; Endothelin B Receptor Antagonists; Endothelin-1; Male; Pain; Pain Threshold; Pyrrolidines; Pyrrolidinones; Rats; Rats, Wistar; Sulfonamides; Time Factors; Trigeminal Neuralgia | 2006 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
ETB receptor dependent alteration in aortic responses to ET-1 in the cardiomyopathic hamster.
Topics: Animals; Aorta; Atrasentan; Cardiomyopathy, Dilated; Cricetinae; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelium, Vascular; In Vitro Techniques; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Vasoconstriction | 2006 |
Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Atrasentan; Cell Proliferation; Cisplatin; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Involvement of the endothelin ET(B) receptor in gender differences in deoxycorticosterone acetate-salt-induced hypertension.
Topics: Animals; Aorta, Thoracic; Atrasentan; Blood Pressure; Desoxycorticosterone; Dopamine beta-Hydroxylase; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Injections, Subcutaneous; Male; Mice; Mice, Knockout; Mice, Transgenic; Organ Size; Ovariectomy; Pyrrolidines; Rats; Receptor, Endothelin B; Sex Factors; Superoxides; Uterus; Weight Gain | 2007 |
Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.
Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation | 2008 |
Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions.
Topics: Animals; Atrasentan; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; In Vitro Techniques; Isometric Contraction; Lung; Male; Perfusion; Pressure; Pulmonary Artery; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Vascular Resistance; Vasoconstriction; Vasodilation; Viper Venoms | 2007 |
Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atrasentan; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Endothelin A Receptor Antagonists; Endothelin-1; Enzyme Activation; Intracellular Signaling Peptides and Proteins; Janus Kinase 2; Male; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein Tyrosine Phosphatases; Pyrrolidines; Rats; Receptor, Angiotensin, Type 1; Receptor, Endothelin A; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Tetrazoles; Time Factors; Tyrphostins; Vasodilation | 2007 |
Identification and characterization of a dysfunctional cardiac myocyte phenotype: role of bacteria, Toll-like receptors, and endothelin.
Topics: Animals; Atrasentan; Bacteria; Cell Size; Cell Survival; Cells, Cultured; Endothelin Receptor Antagonists; Endothelin-1; Escherichia coli; Female; Gene Expression; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; Pyrrolidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Staphylococcus aureus; Toll-Like Receptors | 2007 |
Role of the endothelin axis in the proliferation of human thyroid cancer cells.
Topics: Adenocarcinoma, Follicular; Aspartic Acid Endopeptidases; Atrasentan; Blotting, Western; Bromodeoxyuridine; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Humans; Immunoradiometric Assay; Metalloendopeptidases; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine; Thyroid Neoplasms | 2007 |
Chronic activation of endothelin B receptors: new model of experimental hypertension.
Topics: Animals; Atrasentan; Blood Pressure; Blood Volume; Cardiac Output; Disease Models, Animal; Diuresis; Drug Administration Schedule; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Heart Rate; Hypertension; Male; Natriuresis; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin B; Stroke Volume; Sulfonamides; Vascular Resistance; Viper Venoms | 2007 |
Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes.
Topics: Animals; Arteries; Atrasentan; Collagenases; Endothelin A Receptor Antagonists; Endothelin-1; Immunohistochemistry; Insulin; Male; Matrix Metalloproteinases; Mesenteric Arteries; Pyrrolidines; Rats; Rats, Mutant Strains; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Recombinant Proteins; Vascular Resistance | 2007 |
Atrasentan treatment of pulmonary vascular disease in piglets with increased pulmonary blood flow.
Topics: Animals; Atrasentan; Blood Pressure; Cardiac Output; Chronic Disease; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation; Hypertension, Pulmonary; Hypertrophy; Immunohistochemistry; Lung; Pulmonary Artery; Pulmonary Circulation; Pyrrolidines; Random Allocation; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine; Vascular Endothelial Growth Factor A | 2007 |
Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Atrasentan; Blotting, Western; Bosentan; Cardiac Pacing, Artificial; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; GAP-43 Protein; Hemodynamics; Hydralazine; Immunohistochemistry; Male; Methoxyhydroxyphenylglycol; Myocardial Infarction; Myocardium; Nerve Growth Factor; Neurofilament Proteins; Norepinephrine; Polymerase Chain Reaction; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
Topics: Acetylcholine; Animals; Atrasentan; Basilar Artery; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms | 2008 |
Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
Topics: Acetylcholine; Animals; Atrasentan; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Male; Mesenteric Arteries; Microcirculation; Myography; Peptides, Cyclic; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Viper Venoms | 2008 |
DOCA-salt treatment enhances responses to endothelin-1 in murine corpus cavernosum.
Topics: Animals; Atrasentan; Desoxycorticosterone; Endothelin A Receptor Antagonists; Endothelin-1; Hypertension; Male; Mice; Mice, Inbred C57BL; Muscle, Smooth; Penile Erection; Penis; Pyrrolidines; RNA, Messenger; Sodium Chloride; Vasodilation | 2008 |
ETA-receptor blockade impairs vasoconstriction after hemorrhage in xenon-anesthetized dogs treated with an AT1-receptor antagonist.
Topics: Anesthesia; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Blood Pressure; Dogs; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hemodynamics; Hemorrhage; Losartan; Pyrrolidines; Vascular Resistance; Vasoconstriction; Vasopressins; Xenon | 2008 |
Nonselective ETA/ETB-receptor blockade increases systemic blood pressure of Bio 14.6 cardiomyopathic hamsters.
Topics: Animals; Atrasentan; Blood Pressure; Cardiomyopathies; Cricetinae; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Heart Failure; Hemodynamics; Mesocricetus; Nitrates; Nitrites; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Ventricular Function, Left | 2008 |
Role of endogenous endothelin-1 in post-ischemic cardiac dysfunction and norepinephrine overflow in rat hearts.
Topics: Animals; Aspartic Acid Endopeptidases; Atrasentan; Endothelin-1; Endothelin-Converting Enzymes; Enzyme Inhibitors; Glycopeptides; Male; Metalloendopeptidases; Myocardial Ischemia; Myocardial Reperfusion Injury; Norepinephrine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Sulfonamides; Sulfonylurea Compounds | 2008 |
Targeted therapy in prostate cancer--are we our own worst enemy?
Topics: Atrasentan; Endothelin-1; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Pyrrolidines | 2008 |
Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension.
Topics: Animals; Atrasentan; Blood Pressure; Desoxycorticosterone; Dose-Response Relationship, Drug; Endothelin B Receptor Antagonists; Endothelin-1; Erectile Dysfunction; Gene Expression; Hypertension; In Vitro Techniques; Male; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Penis; Pyrrolidines; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; RNA, Messenger | 2008 |
Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway.
Topics: Animals; Aorta; Atrasentan; Blood Pressure; Endothelin A Receptor Antagonists; Endothelin-1; Endothelins; Flavonoids; Humans; Infusion Pumps, Implantable; Interleukin-10; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Recombinant Proteins; RNA, Messenger; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha; Vasoconstriction | 2009 |
Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats.
Topics: Animals; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Kidney Medulla; Male; Natriuresis; Pyrrolidines; Rats; Rats, Inbred WKY; Rats, Mutant Strains; Receptor, Endothelin A; Receptor, Endothelin B; Regional Blood Flow; Sex Characteristics; Sodium | 2009 |
Endothelial endothelin-1 over-expression using receptor tyrosine kinase tie-1 promoter leads to more severe vascular permeability and blood brain barrier breakdown after transient middle cerebral artery occlusion.
Topics: Animals; Aquaporin 4; Atrasentan; Blood-Brain Barrier; Brain; Capillary Permeability; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Immunoglobulins; Infarction, Middle Cerebral Artery; Matrix Metalloproteinase 2; Membrane Glycoproteins; Membrane Proteins; Mice; Mice, Transgenic; NADPH Oxidase 2; NADPH Oxidases; Occludin; Oxidative Stress; Promoter Regions, Genetic; Pyrrolidines; Receptor, Endothelin A; Receptor, TIE-1; Superoxides; Tyrosine; Water | 2009 |
Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.
Topics: Animals; Antihypertensive Agents; Aorta, Thoracic; Atrasentan; Dinoprost; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelium, Vascular; In Vitro Techniques; Male; Nitroarginine; Oligopeptides; Piperidines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Endothelin A; Receptor, Endothelin B; Tunica Intima; Tunica Media; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Venae Cavae; Viper Venoms | 2009 |
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Endothelin-1; Hydralazine; Hypertension, Malignant; Losartan; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Insufficiency | 2009 |
Endothelin-A-receptor antagonism with atrasentan exhibits limited activity on the KU-19-19 bladder cancer cell line in a mouse model.
Topics: Animals; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Mitosis; Necrosis; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymus Gland; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2009 |
Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.
Topics: Animals; Atrasentan; Autoantibodies; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Kidney; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy, Animal; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1 | 2009 |
O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin 1.
Topics: Acetylglucosamine; Animals; Aorta, Thoracic; Atrasentan; Blood Pressure; Blotting, Western; Desoxycorticosterone; Drug Synergism; Endothelin-1; Glycoproteins; Glycosylation; Hypertension; In Vitro Techniques; Male; N-Acetylglucosaminyltransferases; Phenylephrine; Pyrrolidines; Rats; Rats, Wistar; Time Factors; Vasoconstriction; Vasoconstrictor Agents | 2010 |
Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrasentan; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Synergism; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Phosphorylation; Pyrrolidines; Receptor, Endothelin A; Trastuzumab | 2010 |
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats.
Topics: Analysis of Variance; Animals; Atrasentan; Blood Pressure Determination; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Pregnancy Proteins; Pregnancy, Animal; Probability; Pyrrolidines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vascular Endothelial Growth Factor Receptor-1 | 2010 |
Endothelin receptor subtype A blockade does not affect the haemodynamic recovery from haemorrhage during xenon/remifentanil or isoflurane/remifentanil anaesthesia in dogs.
Topics: Anesthesia; Anesthesia, Inhalation; Anesthesia, Intravenous; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Atrasentan; Blood Loss, Surgical; Catecholamines; Dog Diseases; Dogs; Endothelin A Receptor Antagonists; Endothelin-1; Epinephrine; Female; Hemodynamics; Hemorrhage; Isoflurane; Norepinephrine; Piperidines; Pyrrolidines; Remifentanil; Time Factors; Vascular Resistance; Vasopressins; Xenon | 2010 |
Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.
Topics: Animals; Atrasentan; Bosentan; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Hypovolemia; Lipopolysaccharides; Male; Mesentery; Myography; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Spleen; Sulfonamides; Vasoconstriction | 2010 |
Selective in vivo antagonism of endothelin receptors in transforming growth factor-beta1 transgenic mice that mimic the vascular pathology of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Animals; Atrasentan; Blood Vessels; Brain; Cerebral Arteries; Cerebrovascular Circulation; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Female; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitric Oxide; Nitroarginine; Pyrrolidines; Transforming Growth Factor beta1; Vasoconstriction; Vasodilation; Vasodilator Agents; Vibrissae | 2010 |
ETA receptors are present in human aortic vascular endothelial cells and modulate intracellular calcium.
Topics: Adolescent; Adult; Aorta; Atrasentan; Calcium Signaling; Cell Membrane; Cell Nucleus; Cytosol; Egtazic Acid; Endothelial Cells; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Middle Aged; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Young Adult | 2010 |
Attenuation of streptozotocin-induced microvascular changes in the mouse retina with the endothelin receptor A antagonist atrasentan.
Topics: Administration, Oral; Animals; Atrasentan; Blood Flow Velocity; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin A Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique, Indirect; Male; Mice; Mice, Inbred C57BL; Platelet Endothelial Cell Adhesion Molecule-1; Pyrrolidines; Regional Blood Flow; Retinal Vessels | 2010 |
Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat.
Topics: Analysis of Variance; Animals; Atrasentan; Blood Pressure; Endothelin Receptor Antagonists; Endothelin-1; Immunoassay; Immunohistochemistry; Inflammation; Kidney Glomerulus; Male; Permeability; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin | 2010 |
Effects of exogenous big endothelin-1 on postischemic cardiac dysfunction and norepinephrine overflow in rat hearts.
Topics: Animals; Aspartic Acid Endopeptidases; Atrasentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Male; Metalloendopeptidases; Myocardial Reperfusion Injury; Norepinephrine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfonylurea Compounds; Ventricular Dysfunction, Left | 2011 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; Dinoprost; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Fibrosis; Gout Suppressants; Hypertrophy, Left Ventricular; Hyperuricemia; Isoprostanes; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; RNA, Messenger; Spin Labels; Superoxides; Time Factors; Up-Regulation; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2011 |
The effect of endothelin receptor A antagonism on basilar artery endothelium-dependent relaxation after ischemic stroke.
Topics: Acetylcholine; Animals; Atrasentan; Basilar Artery; Brain Ischemia; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Male; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Reperfusion Injury; Stroke; Vasodilation | 2012 |
Reduced NO production rapidly aggravates renal function through the NF-κB/ET-1/ETA receptor pathway in DOCA-salt-induced hypertensive rats.
Topics: Animals; Atrasentan; Desoxycorticosterone; Disease Models, Animal; Disease Susceptibility; Endothelin-1; Hypertension; Kidney Diseases; Male; NF-kappa B; Nitric Oxide; Nitroarginine; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Severity of Illness Index; Sodium Chloride, Dietary; Thiocarbamates | 2012 |
Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system.
Topics: Adoptive Transfer; Animals; Atrasentan; Blood Pressure; CD4-Positive T-Lymphocytes; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Ischemia; Models, Animal; Placenta; Pregnancy; Pregnancy, Animal; Pyrrolidines; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Messenger; Signal Transduction; Uterus | 2012 |
Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.
Topics: Animals; Atrasentan; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Kidney Failure, Chronic; Male; Mice; Mice, Inbred Strains; Oligopeptides; Piperidines; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Renal Insufficiency, Chronic; Reperfusion Injury; RNA, Messenger | 2013 |
High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin-1; Female; Hypertension; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NG-Nitroarginine Methyl Ester; Peptides, Cyclic; Pyrrolidines; Receptor, Bradykinin B2; Sodium; Sodium Chloride, Dietary; Telemetry | 2013 |
Endothelin receptor blockade ameliorates renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Desoxycorticosterone Acetate; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Gene Expression Regulation; Hypertension; Kidney; Male; Proteinuria; Pyrrolidines; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Sodium Chloride, Dietary | 2014 |
Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice.
Topics: Animals; Apoptosis; Atrasentan; Cell Count; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelin Receptor Antagonists; Endothelin-1; Female; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Inbred C57BL; Pyrrolidines; Retinal Ganglion Cells; Retinal Vessels | 2014 |
Inducible human endothelin-1 overexpression in endothelium raises blood pressure via endothelin type A receptors.
Topics: Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Humans; Hypertension; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Tamoxifen; Up-Regulation | 2015 |
Hypertension in an Animal Model of HELLP Syndrome is Associated With Activation of Endothelin 1.
Topics: Animals; Atrasentan; Disease Models, Animal; Endoglin; Endothelin-1; Female; HELLP Syndrome; Hypertension; Placenta; Pregnancy; Pyrrolidines; Rats; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Sex-Specific Effect of Endothelin in the Blood Pressure Response to Acute Angiotensin II in Growth-Restricted Rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Blood Pressure; Blotting, Western; Enalapril; Endothelin Receptor Antagonists; Endothelin-1; Female; Fetal Growth Retardation; Glomerular Filtration Rate; Hemodynamics; Kidney; Male; Ovariectomy; Pregnancy; Pyrrolidines; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Reverse Transcriptase Polymerase Chain Reaction; Sex Factors | 2015 |
Loss of endothelin B receptor function impairs sodium excretion in a time- and sex-dependent manner.
Topics: Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Female; Male; Natriuresis; Pyrrolidines; Rats; Rats, Inbred WKY; Rats, Transgenic; Receptor, Endothelin B; Sex Factors; Sodium; Time Factors | 2016 |
Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease.
Topics: Animals; Aorta, Thoracic; Atrasentan; Biomarkers; Blood Pressure; Calcium; Calgranulin A; Calgranulin B; Endothelin A Receptor Antagonists; Endothelin-1; Inflammation; Interleukin-1beta; Interleukin-6; Macrophages; Male; Phosphorus, Dietary; Pulse Wave Analysis; Pyrrolidines; Rats; Rats, Wistar; Receptor, Endothelin A; Renal Insufficiency, Chronic; Tumor Necrosis Factor-alpha; Vascular Calcification; Vascular Stiffness; Vitamin D | 2017 |
Effects of systemic and renal intramedullary endothelin-1 receptor blockade on tissue NO and intrarenal hemodynamics in normotensive and hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Hemodynamics; Hypertension; Kidney; Nitric Oxide; Oligopeptides; Piperidines; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Endothelin A; Renal Elimination | 2021 |
Atrasentan: The Difficult Task of Integrating Endothelin A Receptor Antagonists into Current Treatment Paradigm for Diabetic Kidney Disease.
Topics: Albuminuria; Atrasentan; Diabetes Mellitus; Diabetic Nephropathies; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Pyrrolidines | 2021 |
Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Endothelin-1; Endothelins; Fistula; Heart Failure; Hypertension; Rats; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A | 2023 |